Bridgewater Associates LP Sells 15,389 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bridgewater Associates LP cut its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 65.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,083 shares of the medical instruments supplier's stock after selling 15,389 shares during the quarter. Bridgewater Associates LP's holdings in LeMaitre Vascular were worth $751,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. NBC Securities Inc. increased its holdings in shares of LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock worth $40,000 after acquiring an additional 183 shares during the period. GAMMA Investing LLC boosted its position in shares of LeMaitre Vascular by 57.0% during the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier's stock worth $45,000 after buying an additional 199 shares during the period. West Oak Capital LLC bought a new position in LeMaitre Vascular in the 2nd quarter worth approximately $58,000. USA Financial Formulas acquired a new stake in LeMaitre Vascular in the 3rd quarter valued at approximately $60,000. Finally, nVerses Capital LLC raised its stake in LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier's stock valued at $66,000 after acquiring an additional 200 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Bridget A. Ross sold 3,750 shares of the business's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.79% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Barrington Research upped their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research note on Friday, November 1st. StockNews.com lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. JMP Securities boosted their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 20th. Oppenheimer reaffirmed an "outperform" rating and issued a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a "neutral" rating and a $96.00 target price for the company. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, LeMaitre Vascular presently has a consensus rating of "Moderate Buy" and a consensus target price of $94.57.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT traded down $0.45 during midday trading on Tuesday, reaching $105.02. The company's stock had a trading volume of 121,014 shares, compared to its average volume of 123,616. The business's fifty day simple moving average is $95.80 and its 200-day simple moving average is $88.23. The company has a market capitalization of $2.36 billion, a P/E ratio of 57.63, a P/E/G ratio of 2.62 and a beta of 0.93. LeMaitre Vascular, Inc. has a fifty-two week low of $52.55 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analysts' expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm's quarterly revenue was up 15.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.33 earnings per share. On average, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.61%. LeMaitre Vascular's payout ratio is 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.